ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of “Buy” from Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR) have earned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $9.50.

A number of equities analysts recently weighed in on the stock. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Monday, March 10th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price on the stock. HC Wainwright lifted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.14 on Wednesday. The company has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $2.52. ProQR Therapeutics has a one year low of $1.07 and a one year high of $4.62. The stock has a market capitalization of $119.94 million, a price-to-earnings ratio of -3.56 and a beta of 0.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alpine Global Management LLC purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $39,000. Woodline Partners LP acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $9,426,000. Velan Capital Investment Management LP bought a new stake in ProQR Therapeutics during the fourth quarter valued at $107,000. Squarepoint Ops LLC grew its position in shares of ProQR Therapeutics by 16.3% during the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 11,623 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in shares of ProQR Therapeutics by 512.8% during the 4th quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock worth $1,015,000 after purchasing an additional 320,614 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).